Please note: The information displayed on this page might be outdated.
Albumedix: Unique, integrated biotech company with a strong pedigree and ambitious pipeline of marketed and clinical-stage albumin-enabled therapeutics developed with partners, including among others CSL Behring, Merck and GSK. The company’s Veltis® platform of engineered recombinant albumins, can precisely modulate drug half-life, and even enable tissue specific targeting for systemic delivery. Albumedix is creating a pipeline of proprietary and co-developed albumin-enabled therapies.
Company Participants at Danish Science and The City DKBIO 17
- [contact has been deleted]
- Svend Erik Licht, CCO